Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Neon Therapeutics, Inc. | exhibit312.htm |
| EX-31.1 - EXHIBIT 31.1 - Neon Therapeutics, Inc. | exhibit311.htm |
| 10-Q - 10-Q - Neon Therapeutics, Inc. | ntgn-20200331x10q.htm |
Exhibit 32.1
CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Neon Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
(1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 1, 2020 | By: | /s/ Hugh O'Dowd |
Hugh O’Dowd | ||
President, Chief Executive Officer (Principal Executive Officer) | ||
Date: May 1, 2020 | By: | /s/ Yasir B. Al-Wakeel |
Yasir B. Al-Wakeel, B.M.B.Ch. | ||
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | ||